Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

BİLİR, CEMİL; Yildiz, Ibrahim; Bilici, Ahmet; UÇAR, Mahmut; Berk, Veli; Yildiz, Yasar; Yazici, Ozan; Imamoglu, Goksen; Karadurmus, Nuri; Pilanci, Kezban; Arpaci, Erkan; TANRIVERDİ, ÖZGÜR; Karci, Ebru; Temiz, Suleyman; Nayir, Erdinc; Oktay, Esin; Dal, Pinar; Petekkaya, Ibrahim; VARIM, CEYHUN; Cinemre, Hakan

doi:10.1080/07357907.2017.1292518

Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

Atıf İçin Kopyala

BİLİR C., Yildiz I., Bilici A., UÇAR M., Berk V., Yildiz Y., ...Daha Fazla

CANCER INVESTIGATION, cilt.35, sa.4, ss.248-255, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 35 Sayı: 4
Basım Tarihi: 2017
Doi Numarası: 10.1080/07357907.2017.1292518
Dergi Adı: CANCER INVESTIGATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.248-255
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.